Trial reportEye (London, England)2017
One-year real-world outcomes in patients receiving fixed-dosing aflibercept for neovascular age-related macular degeneration.
Trial report in Eye (London, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Sustainability in medical retina: the environmental impact of using aflibercept 8 mg instead of aflibercept 2 mg in treatment-naïve patients with nAMD.Eye (London, England) · 2025Article
- Review of Guideline Recommendations for Optimal Anti-VEGF Therapy in Age-Related Macular Degeneration.Life (Basel, Switzerland) · 2024Review
- Psychophysical, electrofunctional, and morphological evaluation in naïve neovascular AMD patients treated with intravitreal anti-VEGF.Aging medicine (Milton (N.S.W)) · 2024Article
- Cost impact of different treatment regimens of brolucizumab in neovascular age-related macular degeneration: A budget impact analysis.Journal of managed care & specialty pharmacy · 2022Article
- Managing Neovascular Age-Related Macular Degeneration in Clinical Practice: Systematic Review, Meta-Analysis, and Meta-Regression.Journal of clinical medicine · 2022Review
- Three-Year Outcomes of Wet Age-Related Macular Degeneration Treatment in Polish Therapeutic Programs.Medicina (Kaunas, Lithuania) · 2021Article
- Nanotechnology for Age-Related Macular Degeneration.Pharmaceutics · 2021Review
- Evolution of treatment paradigms in neovascular age-related macular degeneration: a review of real-world evidence.The British journal of ophthalmology · 2021Review
- 2-Year Real-World Outcomes with Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration: Literature Review and Meta-analysis of Patient-Relevant Outcomes.Ophthalmology and therapy · 2021Review
- Clinical and economic burden of neovascular age-related macular degeneration by disease status: a US claims-based analysis.Journal of managed care & specialty pharmacy · 2021Article
- Aflibercept Treatment Results and Association with Baseline Characteristics in Cases of Newly Diagnosed Neovascular Age-Related Macular DegenerationTurkish journal of ophthalmology · 2021Article
- Treat-and-extend versus fixed bimonthly treatment regimens for treatment-naive neovascular age-related macular degeneration: real world data from the Fight Retinal Blindness registry.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2021Observational
- Intravitreal Aflibercept Treatment Strategies in Routine Clinical Practice of Neovascular Age-Related Macular Degeneration in Belgium: A Retrospective Observational Study.Ophthalmology and therapy · 2020Article
- Trends in Real-World Neovascular AMD Treatment Outcomes in the UK.Clinical ophthalmology (Auckland, N.Z.) · 2020Review
- The results of aflibercept therapy as a first line treatment of age-related macular degeneration.Journal of current ophthalmology · 2019Article
- Action on neovascular age-related macular degeneration (nAMD): recommendations for management and service provision in the UK hospital eye service.Eye (London, England) · 2019Article
- New artery of knowledge: 3D models of angiogenesis.Vascular biology (Bristol, England) · 2019Review
- Comment on: 'One-year real-world outcomes in patients receiving fixed-dosing aflibercept for neovascular age-related macular degeneration'.Eye (London, England) · 2018Article
- Reply to: 'Comment on: 'One-year real-world outcomes in patients receiving fixed-dosing aflibercept for neovascular age-related macular degeneration'.Eye (London, England) · 2018Article
- Aflibercept treatment for neovascular AMD beyond the first year: consensus recommendations by a UK expert roundtable panel, 2017 update.Clinical ophthalmology (Auckland, N.Z.) · 2017Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PurposeTo investigate 1-year visual and anatomic outcomes of intravitreal aflibercept for neovascular age-related macular degeneration (nAMD) given at a fixed 8-weekly interval.MethodsRetrospective, single-practice data analysis from an electronic medical record system of 255 eyes (223 patients) with treatment-naïve nAMD receiving 8-weekly aflibercept.ResultsMean logarithm of the minimum angle of resolution best-corrected visual acuity (BCVA) improved from 0.66 at baseline to 0.50 at month 11 (P<0.0001). Mean central retinal thickness (CRT) decreased from 311 μm at baseline to 211 μm at month 11 (P<0.0001). Our mean VA gain of eight ETDRS letters was comparable to the VIEW 1 and VIEW 2 Trials' results at the end of year 1. After loading at month 5, mean BCVA was 0.48 (P<0.0001), and mean CRT was 235 μm. At month 5, 143 eyes (56%) were inactive defined by the absence of macular haemorrhage and intraretinal fluid (IRF) and subretinal fluid (SRF) on optical coherence tomography, and 112 eyes (44%) remained active. At month 11, 136 eyes (53%) were inactive, and 119 eyes (47%) remained active. At month 11, 77% of inactive eyes after loading remained inactive, and 77% of the active eyes after loading remained active. At month 11, mean BCVA of the inactive group was 0.51, and mean BCVA of the active group was 0.48 (P=0.54).ConclusionsAflibercept administered by fixed dosing over 1 year improved VA and macular morphology in treatment-naïve eyes. Active lesions at month 11 do not have worse VA outcomes compared with inactive lesions. The macular status after loading is a reliable indicator of disease activity at the end of year 1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.